Analysis of WHO-Based Prognostic Scoring System(WPSS) of Myelodysplastic Syndrome and Its Comparison with International Prognostic Scoring System(IPSS) in 100 Chinese Patients

被引:0
|
作者
Jia Wei1
机构
关键词
WPSS; IPSS; RBC transfusion dependency; Time-dependent; Prognosis;
D O I
暂无
中图分类号
R55 [血液及淋巴系疾病];
学科分类号
1002 ; 100201 ;
摘要
Objective:The aims of this study were to assess the prognostic significance of WHO-based Prognostic Scoring System(WPSS) in myelodysplastic syndrome(MDS) from a single center institute and to compare WPSS with the international prognostic scoring system(IPSS). Methods:A total of 100 cases with de novo MDS were reviewed and their karyotypes were detected. All of them were followed up and classified according to IPSS and WPSS risk groups. SPSS 13.0 software was applied to deal with all the data. The statistical methods included Kaplan - Meier,Log-rank test and cox regression. Results:Multivariate cox regression analysis indicated that WHO Classification(P=0.0190),karyotype abnormalities categorized according to IPSS(P=0.0159) and red blood cell(RBC) transfusion(P=0.0009) were the three most important independent factors for predicting overall survival(OS) of MDS. WPSS and IPSS both had great capacity in predicting the OS of MDS at the time of diagnosis(P<0.0001). In time-dependent analysis,WPSS can predict the OS accurately in the following three years after diagnosis(P<0.0001),while IPSS failed to predict the OS 24 months after diagnosis(P=0.1094). Conclusion:Our single center results proved that WPSS is a dynamic prognostic system which can predict the OS of MDS patients at any time during the course of their disease. This time-dependent prognostic scoring system may replace the IPSS in the near future.
引用
收藏
页码:50 / 55
页数:6
相关论文
共 50 条
  • [21] Delayed response to lenalidomide in International Prognostic Scoring System (IPSS) low risk myelodysplastic syndrome (MDS)
    Tubb, Erev E.
    Besa, Emmanuel C.
    Giagounidis, Aristoteles
    Fonseca, Gustavo A.
    BLOOD, 2007, 110 (11) : 433A - 434A
  • [22] International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
    Hasle, H
    Baumann, I
    Bergsträsser, E
    Fenu, S
    Kardos, G
    Kerndrup, G
    Manne, G
    Rogge, T
    Schultz, KR
    Stary, J
    van Wering, E
    Harbott, J
    Nöllke, P
    Niemeyer, CM
    BLOOD, 2001, 98 (11) : 624A - 624A
  • [23] The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)
    Hasle, H
    Baumann, I
    Bergsträsser, E
    Fenu, S
    Fischer, A
    Kardos, G
    Kerndrup, G
    Locatelli, F
    Rogge, T
    Schultz, KR
    Stary, J
    Trebo, M
    van den Heuvel-Eibrink, MM
    Harbott, J
    Nöllke, P
    Niemeyer, CM
    LEUKEMIA, 2004, 18 (12) : 2008 - 2014
  • [24] Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS)
    Alessandrino, Emilio Paolo
    Della Porta, Matteo G.
    Malcovati, Luca
    Jackson, Christopher H.
    Pascutto, Cristiana
    Bacigalupo, Andrea
    van Lint, Maria Teresa
    Falda, Michele
    Bernardi, Massimo
    Onida, Francesco
    Guidi, Stefano
    Iori, Anna Paola
    Cerretti, Raffaella
    Marenco, Paola
    Pioltelli, Pietro
    Angelucci, Emanuele
    Oneto, Rosi
    Rambaldi, Alessandro
    Bosi, Alberto
    Cazzola, Mario
    BLOOD, 2011, 118 (21) : 57 - 57
  • [25] The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)
    H Hasle
    I Baumann
    E Bergsträsser
    S Fenu
    A Fischer
    G Kardos
    G Kerndrup
    F Locatelli
    T Rogge
    K R Schultz
    J Starý
    M Trebo
    M M van den Heuvel-Eibrink
    J Harbott
    P Nöllke
    C M Niemeyer
    Leukemia, 2004, 18 : 2008 - 2014
  • [26] THE ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM
    Bolaman, A. Z.
    Yavasoglu, I.
    Kadikoylu, V. G.
    Pektas, G.
    HAEMATOLOGICA, 2014, 99 : 625 - 625
  • [27] Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)
    Kantarjian, Hagop M.
    O'Brien, Susan
    Ravandi, Farhad
    Cortes, Jorge
    Shan, Jianqin
    Bennett, John M.
    List, Alan F.
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    BLOOD, 2008, 112 (11) : 236 - 237
  • [28] CLINICIAN UTILIZATION OF THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) FOR NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS
    Pease, D.
    Ross, J.
    Poynter, J.
    Nguyen, P.
    Hirsch, B.
    Cioc, A.
    Roesler, M.
    Warlick, E.
    LEUKEMIA RESEARCH, 2015, 39 : S118 - S118
  • [29] Delayed response to lenalidomide in International Prognostic Scoring System (IPSS) low-risk myelodysplastic syndrome (MDS)
    Garcia, A. Mejia
    Asija, A.
    Besa, E. C.
    Giagounidis, A.
    Fonseca, G. A.
    LEUKEMIA RESEARCH, 2013, 37 : S111 - S111
  • [30] Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes
    Huang, Nanfang
    Song, Yang
    Wu, Lingyun
    He, Qi
    Zhang, Zheng
    Guo, Juan
    Xu, Feng
    Chang, Chunkang
    Li, Xiao
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 193 - 206